Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22695293 | 0.87 | HTR2B (0.46) | NPC1RAB9APTGDR2MAPTHTR2B | |
| SCHEMBL9192117 | 0.87 | HTR2B (0.49) | NPC1RAB9APTGDR2MAPTHTR2B | |
| SCHEMBL12035517 | 0.87 | RAB9A (0.49) | NPC1RAB9AMAPTHTR2BHTR2A | |
| SCHEMBL3691062 | 0.86 | PTGDR2 (0.68) | NPC1RAB9APTGDR2MAPTTSHR | |
| SCHEMBL11280539 | 0.83 | NPC1 (0.61) | NPC1RAB9APTGDR2MAPTTSHR | |
| SCHEMBL22688831 | 0.81 | PTGDR2 (0.75) | NPC1RAB9APTGDR2TSHRKMT2A | |
| SCHEMBL13446708 | 0.81 | NPC1 (0.54) | NPC1RAB9APTGDR2MAPTTSHR | |
| SCHEMBL22591956 | 0.80 | TDP1 (0.62) | MAPTHTR2BHTR2AHTR2CTSHR | |
| SCHEMBL1714092 | 0.80 | NPC1 (0.54) | NPC1RAB9APTGDR2MAPTTSHR | |
| SCHEMBL11155751 | 0.80 | NPC1 (0.54) | NPC1RAB9APTGDR2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974434-B1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12410191-B2 | Macrolide derivatives, preparation method and application thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| CN-113727984-B | Macrocyclic derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20220235070-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI ARYL PHARMTECH CO., LTD. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3974434-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| CN-113727984-A | Macrocyclic derivative, preparation method and application thereof | 浙江海正药业股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2020233645-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | 浙江海正药业股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2319831-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDE GROUP, AMINOCARBONYL GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | IL6, IL6ST, UACA | NPC1 3855/4885RAB9A 1863/4885PTGDR2 222/4885 |
| US-20220235070-A1 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | ROS1, IRAK1, IRAK2 | NPC1 353/4885RAB9A 1177/4885PTGDR2 3764/4885 |
| US-12410191-B2 | Macrolide derivatives, preparation method and application thereof | ROS1, IRAK1, IRAK2 | NPC1 353/4885RAB9A 1177/4885PTGDR2 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.